Rhythm Pharmaceuticals, Inc. RYTM Foreign currency translation gains (losses)
Foreign currency translation gains (losses) at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax.
The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rhythm Pharmaceuticals, Inc.'s foreign currency translation gains (losses).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s foreign currency translation gains (losses)?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported foreign currency translation gains (losses) of $1.78M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s foreign currency translation gains (losses) changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s foreign currency translation gains (losses) increased by 89300.0% year-over-year, from -$2K to $1.78M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s foreign currency translation gains (losses)?
- Over 2 years (2023 to 2025), Rhythm Pharmaceuticals, Inc.'s foreign currency translation gains (losses) has grown at a 201.4% compound annual growth rate (CAGR), from -$140K to -$1.27M.
- What does foreign currency translation gains (losses) mean?
- This captures the gains or losses resulting from translating the financial statements of foreign subsidiaries into the company's reporting currency. It reflects the impact of exchange rate fluctuations on the value of international assets and liabilities. This metric is essential for understanding the volatility introduced by global operations.